E2F1 and cancer: These observations indicate that utilizing deregulated E2F activity in cancer cells by tumor suppressor promoter elements has significant advantages over growth-related E2F target promoters, such as E2F1, regulated by enhanced E2F activity, in order to drive therapeutic gene expression specifically in cancer cells.